J.C. Rwigema
Papers
2
Total Citations
69
H-Index
2
About
Dr. J.C. Rwigema is a leading clinical researcher in head and neck oncology, with a focused expertise in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Their major contribution lies in pioneering de-escalation treatment strategies to reduce treatment toxicity without compromising oncologic outcomes. Dr. Rwigema is the principal investigator of the landmark Phase III trial MC1675 (53 citations), which evaluates de-escalated adjuvant radiation therapy (DART) against standard adjuvant treatment for HPV-positive oropharyngeal cancer—a study that has reshaped clinical equipoise in the field. Their work also includes a critical retrospective analysis of two prospective de-escalation trials (MC1273 & MC1675, 16 citations), providing the first comprehensive 30-day morbidity and mortality data after transoral robotic surgery in this patient population. By demonstrating that carefully selected patients can safely receive less intensive therapy, Dr. Rwigema’s research directly improves quality of life for survivors while maintaining high cure rates. Their findings are increasingly cited in national treatment guidelines and have established them as a key voice in the movement toward personalized, de-intensified care for HPV-driven head and neck cancers.
Research Focus
Key Achievements
Top Papers
- 1
- 2